Know Cancer

forgot password

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Phase 2
Not Enrolling
Neuroendocrine Tumors, Carcinoid Tumors, Adrenal Gland Tumors, Neuroblastoma, Pancreatic Neuroendocrine Tumors, Multiple Endocrine Neoplasia

Thank you

Trial Information

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Inclusion Criteria:

Subjects must be treated at Stanford University Medical Center for the entire length of
study participation.

1. Patients must have histologically or cytologically confirmed well-differentiated
neuroendocrine tumor. Patients must be deemed unresectable due to involvement of
critical vasculature or adjacent organ invasion or have metastatic disease.

2. Patients with prior surgical resection who develop radiological or clinical evidence
of metastatic cancer do not require separate histological or cytological confirmation
of metastatic disease unless an interval of > 5 years has elapsed between the primary
surgery and the development of metastatic disease. Clinicians should consider biopsy
of lesions to establish diagnosis of metastatic disease if there is substantial
clinical ambiguity regarding the nature or source of apparent metastases.

3. Prior chemotherapy will be permitted.

4. Prior or concurrent somatostatin analogue use will be permitted.

5. Patients must have a primary or metastatic lesion measurable in at least one
dimension by Modified RECIST criteria (v1.1) within 4 weeks prior to entry of study.

6. Patients must have ECOG performance status of 0-2.

7. Patients must be >= 18 years of age.

8. Laboratory values <= 2 weeks prior to randomization:

- Absolute Neutrophil Count (ANC) >= 1.5 x 109/L (>= 1500/mm3)

- Platelets (PLT) >= 50 x 109/L (>= 100,000/mm3) (or >= 25 x 109/L (>=
100,000/mm3) if thrombocytopenia is secondary to a non-myelosuppressive cause
such as splenic sequestration).

- Hemoglobin (Hgb) >= 9 g/dL

- Serum creatinine <= 1.5 x ULN

- Serum bilirubin <= 1.5 x ULN (<= 3.0 x ULN if liver metastases present)

- Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) <=
3.0 x ULN (<= 5.0 x ULN if liver metastases present). Note: ERCP or
percutaneous stenting may be used to normalize the liver function tests.

- Albumin >= 1.5

9. LVEF by TTE or MUGA >= 50%

10. Life expectancy >= 12 weeks

11. Ability to give written informed consent according to local guidelines

Exclusion Criteria:

1. Disease-Specific Exclusions

1. Prior full field radiotherapy <= 4 weeks or limited field radiotherapy <= 2
weeks prior to enrollment. Patients must have recovered from all
therapy-related toxicities. The site of previous radiotherapy should have
evidence of progressive disease if this is the only site of disease.

2. Prior biologic or immunotherapy <= 2 weeks prior to registration. Patients must
have recovered from all therapy-related toxicities

3. If history of other primary cancer, subject will be eligible only if she or he

- Curatively resected non-melanomatous skin cancer

- Curatively treated cervical carcinoma in situ

- Other primary solid tumor curatively treated with no known active disease
present and no treatment administered for the last 3 years

4. Concurrent use of other investigational agents and patients who have received
investigational drugs <= 4 weeks prior to enrollment.

2. General Medical Exclusions

1. Subjects known to have chronic or active hepatitis B or C infection with
impaired hepatic function (ineligible if AST and ALT > 3.0 x ULN).

2. History of any medical or psychiatric condition or laboratory abnormality that
in the opinion of the investigator may increase the risks associated with study
participation or study drug administration or may interfere with the conduct of
the study or interpretation of study results

3. Male subject who is not willing to use adequate contraception upon enrollment
into this study and for 6 months following the last dose of second-line

4. Female subject (of childbearing potential, post-menopausal for less than 6
months, not surgically sterilized, or not abstinent) who is not willing to use
an oral, patch or implanted contraceptive, double-barrier birth control, or an
IUD during the course of the study and for 6 months following the last dose of
second-line treatment

5. Female subject who is breast-feeding or who has positive serum pregnancy test 72
hours prior to randomization

6. Pleural effusion or ascites that causes respiratory compromise (>= CTCAE grade 2

7. Any of the following concurrent severe and/or uncontrolled medical conditions
within 24 weeks of enrollment which could compromise participation in the study:

- Unstable angina pectoris

- Symptomatic congestive heart failure

- Myocardial infarction <= 6 months prior to registration and/or

- Serious uncontrolled cardiac arrhythmia

- Uncontrolled diabetes

- Active or uncontrolled infection

- Interstitial pneumonia or extensive and symptomatic interstitial fibrosis
of the lung

- Chronic renal disease

8. Patients unwilling to or unable to comply with the protocol

9. Life expectancy of less than 12 weeks

10. Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study other than a Genentech-sponsored
cancer study

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate (RR) for all patients treated with this strategy (Simon design)

Outcome Time Frame:

CT scans are done every 4 cycles (every 12 wks)

Safety Issue:


Principal Investigator

Pamela Kunz

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University


United States: Food and Drug Administration

Study ID:




Start Date:

March 2009

Completion Date:

May 2010

Related Keywords:

  • Neuroendocrine Tumors
  • Carcinoid Tumors
  • Adrenal Gland Tumors
  • Neuroblastoma
  • Pancreatic Neuroendocrine Tumors
  • Multiple Endocrine Neoplasia
  • Adrenal Gland Neoplasms
  • Neoplasms
  • Carcinoid Tumor
  • Endocrine Gland Neoplasms
  • Multiple Endocrine Neoplasia
  • Neuroblastoma
  • Neuroendocrine Tumors
  • Adenoma, Islet Cell



Stanford University School of MedicineStanford, California  94305-5317